A grant from the National Institutes of Health awarded to a Weill Cornell Medicine investigator will bolster Akelos Inc.-supported research to develop a non-opioid alternative to treat chronic and neuropathic pain.
NEW YORK, October 4, 2019 (Newswire.com) - A grant from the National Institutes of Health awarded to a Weill Cornell Medicine investigator will bolster Akelos Inc.-supported research to develop a non-opioid alternative to treat chronic and neuropathic pain. Akelos Inc. is in a research collaboration with Weill Cornell Medicine to develop this anti-hyperalgesic drug.
This award is under the Helping to End Addiction Long-term Initiative, or the NIH Heal Initiative; the title of the grant is “Novel HCN1-selective small molecule inhibitors for the treatment of neuropathic pain.” Peter Goldstein, MD, Akelos Inc. scientific founder and a professor of anesthesiology at Weill Cornell Medicine, will serve as the project’s principal investigator. Dr. Goldstein will work on the research with Gareth Tibbs, PhD, Akelos Inc. scientific founder and senior research associate in anesthesiology at Weill Cornell Medicine; Dianna Willis, PhD, an assistant professor of neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine, who received a grant sub-award; and J. David Warren, PhD, an associate professor of research in biochemistry. Drs. Goldstein, Tibbs, Willis and Warren are all members of Akelos Inc.'s Scientific Advisory Board. Dr. Goldstein is a named inventor on patents licensed to Akelos Inc. and Cornell University. Drs. Tibbs and Warren are equity stakeholders in Akelos Inc.
Neuropathic pain is a common clinical disorder for which treatment options are generally ineffective. Degradation of an individual’s quality of life, combined with substantial societal and monetary costs, make this condition a significant and imminent public health threat. The immediate goal of this project is to determine if a novel small molecule alkylphenol that inhibits HCN1 channel function is antihyperalgesic when administered orally. In addition to focusing on the development of an oral drug, the long-term goal is to develop an injectable version of this drug using a monoclonal antibody, thereby creating an urgently needed, highly effective, non-opioid, treatment for neuropathic pain.
“We are thrilled that Dr. Peter Goldstein and his team have received this prestigious and highly competitive peer-reviewed award from the NIH,” said Dr. Steven Fox, chairman of Akelos Inc. “Such support validates his innovative approach and emphasizes the importance of Akelos Inc.'s investment in research and development efforts to help solve this public health crisis.”
This research is supported in part by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number UG3NS114947, and the Weill Cornell Medicine Department of Anesthesiology. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.
For more information, please contact:
Akelos Inc.
Dr. Steven Fox, CEO
212-953-1544
drstevefox@aol.com
About Akelos Inc.
Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-opioid drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs.
Forward-Looking Statement
This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes of events, timing and performance to differ materially from those expressed or implied by such statements. These statements include, among others, those related to: the results of research and development activities, uncertainties relating to preclinical and clinical testing, the cost, timing and outcome of the regulatory development and approval process, our budgets, expenditures and financing plans, our need for substantial additional funds, patent and intellectual property matters, our dependence on third parties, including contract research and contract clinical trial organizations, and market opportunity and competition.
The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
